ArticleBiomolecules & biomedicine2026
Higher serum PFDA is associated with increased non-melanoma skin cancer odds in NHANES 2003-2018.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Per- and polyfluoroalkyl substances (PFAS) are environmentally persistent chemicals commonly employed in heat- and water-resistant applications. Experimental evidence indicates a biological plausibility for PFAS-related carcinogenic effects through mechanisms such as oxidative stress and immunomodulation; however, epidemiological evidence regarding skin cancers remains limited. This study aimed to investigate the association between serum concentrations of three understudied PFAS-perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnDA), and 2-(N-methyl-perfluorooctane sulfonamido) acetic acid (2-(N-methyl-PFOSA) acetate)-and the incidence of non-melanoma skin cancer (NMSC) and melanoma among U.S. adults. We conducted a cross-sectional analysis utilizing data from eight NHANES cycles (2003-2018), which included 5,934 adults aged 20 years and older with complete data. Skin cancer outcomes were determined based on self-reported physician diagnoses, while PFAS concentrations were assessed in serum samples. We employed multivariable logistic regression, adjusting for age, sex, race/ethnicity, body mass index, smoking status, and NHANES cycle. PFAS exposure was evaluated using tertiles, detectable/undetectable status, and log-transformed continuous measures. Additionally, exploratory age- and sex-stratified analyses were conducted using Firth penalized logistic regression, and multiple imputation was applied to address potential selection bias due to missing covariates. Compared to the lowest tertile, PFDA in the second tertile was associated with an increased likelihood of NMSC (adjusted odds ratio [aOR] 1.73, 95% uncertainty interval [UI] 1.01-2.89; p=0.048), although no clear dose-response trend was observed across tertiles. Among adults aged 60 years and older, PFDA in the second tertile was linked to higher odds of NMSC (aOR 2.29, 95% UI 1.29-4.05; p=0.004). Associations for PFUnDA and 2-(N-methyl-PFOSA) acetate were generally inconsistent across exposure metrics, and analyses for melanoma did not reveal a definitive association. These findings suggest a potential link between higher PFDA exposure and NMSC, particularly in older adults, underscoring the necessity for ongoing PFAS monitoring and well-designed prospective studies to elucidate the temporal relationship and causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.